Google+ Badge

Tuesday, January 12, 2016

Cancer Research:Early trial shows injectable agent illuminates cancer during surgery ♦ Painkiller tapped to become future cancer-killer ♦ Potential therapy targets for triple-negative breast cancer

Early trial shows injectable agent illuminates cancer during surgery A new injectable agent has been tested that causes cancer cells in a tumor to fluoresce, potentially increasing a surgeon's ability to locate and remove all of a cancerous tumor on the first attempt.
Unusual drug target, drug generate exciting preclinical results in mouse models of metastatic breast cancer A doctor treating a patient with a potentially fatal metastatic breast tumor would be very pleased to find, after administering a round of treatment, that the primary tumor had undergone a change in character – from aggressive to static, and no longer shedding cells that can colonize distant organs of the body. Indeed, most patients with breast and other forms of cancer who succumb to the illness do so because of the cancer’s unstoppable spread.
Painkiller tapped to become future cancer-killer Diclofenac, a common painkiller, has significant anti-cancer properties, according to researchers. Like other drugs examined by the ReDO project, diclofenac is cheap and readily accessible -- and as it's already present in many medicine cabinets, it has been carefully tested.
Study reveals potential therapy targets for triple-negative breast cancer In cancer, cell signaling pathways are the critical chain of events that can either quash or quicken disease progression. A new study has revealed new information about how molecules called long non-coding RNAs (lncRNA) interact with HIF-1, a signaling pathway that is overexpressed in many cancers. HIF-1 has been shown to regulate breast cancer progression.

No comments:

Post a Comment